{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:47:50Z","timestamp":1782388070033,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BeOne Medicines Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00443-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:51:09Z","timestamp":1778759469000},"page":"519-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2866-2260","authenticated-orcid":false,"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"443_CR1","unstructured":"NCCN Guidelines. Chronic lymphocytic leukemia\/small lymphocytic lymphoma; Version 3.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed Aug 2025."},{"key":"443_CR2","unstructured":"Wendtner CM, Al-Sawaf O, Binder M, et al. Chronic lymphocytic leukemia (CLL). https:\/\/www.onkopedia.com\/en\/onkopedia\/guidelines\/chronic-lymphocytic-leukemia-cll\/@@guideline\/html\/index.html. Accessed Oct 2025."},{"key":"443_CR3","unstructured":"Bussot L, De Guibert S, Dilhuydy MS, et al. Recommandations FILO-LYSA 2025 algorithmes de prise en charge des patients atteints de LLC. https:\/\/www.filo-leucemie.org\/upload\/files\/LLC-Recommandations_FILO_2025.pdf. Accessed Oct 2025."},{"key":"443_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"443_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918\u201332.","journal-title":"JAMA"},{"key":"443_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, et al. ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35:762\u20138.","journal-title":"Ann Oncol"},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase\u00a03 CLL14 study. Blood. 2024;144:1924\u201335.","journal-title":"Blood"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","volume":"25","author":"M Furstenau","year":"2024","unstructured":"Furstenau M, Kater AP, Robrecht S, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase\u00a03 trial. Lancet Oncol. 2024;25:744\u201359.","journal-title":"Lancet Oncol"},{"key":"443_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326\u201337.","journal-title":"N Engl J Med"},{"key":"443_CR10","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. 2026;394(11):1084\u201396.","DOI":"10.1056\/NEJMoa2515458"},{"key":"443_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5\u00a0years of follow-up from the phase\u00a03 RESONATE-2 study. Leukemia. 2020;34:787\u201398.","journal-title":"Leukemia"},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","volume":"26","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase\u00a0Ib\/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918\u201327.","journal-title":"Clin Cancer Res"},{"key":"443_CR13","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363.","journal-title":"Am J Hematol"},{"key":"443_CR14","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910\u20139.","journal-title":"Blood"},{"key":"443_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874\u20139.","journal-title":"Haematologica"},{"key":"443_CR16","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","volume":"104","author":"M Winqvist","year":"2019","unstructured":"Winqvist M, Andersson PO, Asklid A, et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematologica. 2019;104:e208\u201310.","journal-title":"Haematologica"},{"key":"443_CR17","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase\u00a0III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706\u201317.","journal-title":"Blood"},{"key":"443_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Robak T, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2025;43:780\u20137.","journal-title":"J Clin Oncol"},{"key":"443_CR20","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62:7923\u201340.","journal-title":"J Med Chem"},{"key":"443_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, et al. Phase\u00a01 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851\u20139.","journal-title":"Blood"},{"key":"443_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","volume":"14","author":"CS Tam","year":"2021","unstructured":"Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK\/PD translation of the second-generation Bruton\u2019s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14:1329\u201344.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"443_CR23","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","volume":"132","author":"A Kaptein","year":"2018","unstructured":"Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132:1871.","journal-title":"Blood"},{"key":"443_CR24","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829\u201330.","journal-title":"Blood"},{"key":"443_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103238","volume":"159","author":"L Pellegrini","year":"2021","unstructured":"Pellegrini L, Novak U, Andres M, Suter T, Nagler M. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103238.","journal-title":"Crit Rev Oncol Hematol"},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, Salem JE, Clauss S, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142:2443\u201355.","journal-title":"Circulation"},{"key":"443_CR27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298\u2013307.","journal-title":"Blood"},{"key":"443_CR28","first-page":"2277","volume":"109","author":"JR Brown","year":"2024","unstructured":"Brown JR, Ghia P, Jurczak W, et al. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database. Haematologica. 2024;109:2277\u201383.","journal-title":"Haematologica"},{"key":"443_CR29","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1080\/10428194.2021.1929961","volume":"62","author":"YC Ou","year":"2021","unstructured":"Ou YC, Tang Z, Novotny W, et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62:2612\u201324.","journal-title":"Leuk Lymphoma"},{"key":"443_CR30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/bjh.17994","volume":"196","author":"G Cull","year":"2022","unstructured":"Cull G, Burger JA, Opat S, et al. Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase\u00a0I\/II AU-003 study. Br J Haematol. 2022;196:1209\u201318.","journal-title":"Br J Haematol"},{"key":"443_CR31","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1182\/blood-2024-200363","volume":"144","author":"CS Tam","year":"2024","unstructured":"Tam CS, Opat SS, Merriman EG, et al. Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase\u00a01\/2 AU-003 and phase\u00a01b GA-101 studies: a report from the zanubrutinib extension study. Blood. 2024;144:3255\u20137.","journal-title":"Blood"},{"key":"443_CR32","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1007\/s12325-022-02238-7","volume":"39","author":"W Xu","year":"2022","unstructured":"Xu W, Yang S, Tam CS, et al. Zanubrutinib monotherapy for na\u00efve and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: a pooled analysis of three studies. Adv Ther. 2022;39:4250\u201365.","journal-title":"Adv Ther"},{"key":"443_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00884-4","volume":"13","author":"W Xu","year":"2020","unstructured":"Xu W, Yang S, Zhou K, et al. Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase\u00a02, single-arm, multicenter study. J Hematol Oncol. 2020;13:48.","journal-title":"J Hematol Oncol"},{"key":"443_CR34","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1080\/10428194.2022.2164692","volume":"64","author":"W Xu","year":"2023","unstructured":"Xu W, Yang S, Zhou K, et al. Zanubrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. Leuk Lymphoma. 2023;64:712\u20136.","journal-title":"Leuk Lymphoma"},{"key":"443_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase\u00a03 trial. Lancet Oncol. 2022;23:1031\u201343.","journal-title":"Lancet Oncol"},{"key":"443_CR36","doi-asserted-by":"publisher","first-page":"e72_70093","DOI":"10.1002\/hon.70093_72","volume":"43","author":"C Tam","year":"2025","unstructured":"Tam C, Ghia P, Shadman M, et al. SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib in patients with del(17p) and treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Hematol Oncol. 2025;43:e72_70093.","journal-title":"Hematol Oncol"},{"key":"443_CR37","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1200\/JCO-25-00758","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Ma S, et al. Zanubrutinib and venetoclax for patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA arm D results. J Clin Oncol. 2025;43:2409\u201317.","journal-title":"J Clin Oncol"},{"key":"443_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/hon.3163_154","volume":"41","author":"M Shadman","year":"2023","unstructured":"Shadman M, Munir T, Roback T, et al. Zanubrutinib (zanu) versus bendamustine + rituximab (BR) in patients (pts) with treatment-na\u00efve (TN) CLL\/SLL: extended follow-up of the SEQUOIA study. Hematol Oncol. 2023;41:235\u20138.","journal-title":"Hematol Oncol"},{"key":"443_CR39","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328.","journal-title":"N Engl J Med"},{"key":"443_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"443_CR41","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood-2023-173540","volume":"142","author":"V Levy","year":"2023","unstructured":"Levy V, Srivastava T, Yang K, et al. Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia. Blood. 2023;142:1909.","journal-title":"Blood"},{"key":"443_CR42","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","volume":"10","author":"M Shadman","year":"2023","unstructured":"Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase\u00a02, open-label, single-arm study. Lancet Haematol. 2023;10:e35-45.","journal-title":"Lancet Haematol"},{"key":"443_CR43","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1182\/bloodadvances.2024015493","volume":"9","author":"M Shadman","year":"2025","unstructured":"Shadman M, Burke JM, Cultrera J, et al. Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: updated results. Blood Adv. 2025;9:4100\u201310.","journal-title":"Blood Adv"},{"key":"443_CR44","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","volume":"4","author":"CS Tam","year":"2020","unstructured":"Tam CS, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020;4:4802\u201311.","journal-title":"Blood Adv"},{"key":"443_CR45","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1182\/blood-2024-199175","volume":"144","author":"JD Soumerai","year":"2024","unstructured":"Soumerai JD, Cheah CY, Anderson MA, et al. Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase\u00a01\/1b study BGB-11417-101. Blood. 2024;144:1012\u20134.","journal-title":"Blood"},{"key":"443_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7087","volume":"42","author":"M Shadman","year":"2024","unstructured":"Shadman M, Kater AP, Woyach JA, et al. CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase\u00a03 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-na\u00efve (TN) CLL. J Clin Oncol. 2024;42:TPS7087.","journal-title":"J Clin Oncol"},{"key":"443_CR47","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","volume":"8","author":"JD Soumerai","year":"2021","unstructured":"Soumerai JD, Mato AR, Dogan A, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase\u00a02 trial. Lancet Haematol. 2021;8:e879\u201390.","journal-title":"Lancet Haematol"},{"key":"443_CR48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205697","volume":"144","author":"JD Soumerai","year":"2024","unstructured":"Soumerai JD, Dogan A, Seshan V, et al. Multicenter phase\u00a0II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-na\u00efve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (\u0394MRD400). Blood. 2024;144:1867.","journal-title":"Blood"},{"key":"443_CR49","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1182\/blood-2023-174465","volume":"142","author":"JN Allan","year":"2023","unstructured":"Allan JN, Helbig D, Mulvey E, et al. Zanubrutinib and venetoclax as initial therapy for CLL\/SLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG). Blood. 2023;142:3285.","journal-title":"Blood"},{"key":"443_CR50","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/bloodadvances.2024015594","volume":"9","author":"A Barrett","year":"2025","unstructured":"Barrett A, Harris C, Eyre TA. Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review. Blood Adv. 2025;9:2773\u201380.","journal-title":"Blood Adv"},{"key":"443_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000870","volume":"7","author":"C Tam","year":"2023","unstructured":"Tam C, Munoz J, Cull G, et al. Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia. Hemasphere. 2023;7:e870.","journal-title":"Hemasphere"},{"key":"443_CR52","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","volume":"30","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Ligtvoet R, Robrecht S, et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase\u00a02 RT1 trial. Nat Med. 2024;30:240\u20138.","journal-title":"Nat Med"},{"key":"443_CR53","doi-asserted-by":"publisher","first-page":"e47546cf","DOI":"10.1097\/01.HS9.0000969432.47546.cf","volume":"7","author":"S Hwang","year":"2023","unstructured":"Hwang S, Wang J, Tian Z, et al. Comparison of treatment-emergent adverse events of acalabrutinib and zanubrutinib in clinical trials in B-cell malignancies: a systematic review and meta-analysis. Hemasphere. 2023;7:e47546cf.","journal-title":"Hemasphere"},{"key":"443_CR54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011641","author":"JJ Moslehi","year":"2024","unstructured":"Moslehi JJ, Furman RR, Tam CS, et al. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. Blood Adv. 2024. https:\/\/doi.org\/10.1182\/bloodadvances.2023011641.","journal-title":"Blood Adv"},{"key":"443_CR55","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","volume":"6","author":"FT Awan","year":"2022","unstructured":"Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6:5516\u201325.","journal-title":"Blood Adv"},{"key":"443_CR56","unstructured":"BeOne Medicines. Brukinsa (zanubrutinib) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brukinsa-epar-product-information_en.pdf. Accessed Feb 2026."},{"key":"443_CR57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjh.18418","volume":"200","author":"S Nakhoda","year":"2023","unstructured":"Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200:137\u201349.","journal-title":"Br J Haematol"},{"key":"443_CR58","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1182\/blood-2023-173547","volume":"142","author":"JR Brown","year":"2023","unstructured":"Brown JR, Li J, Eichhorst BF, et al. Acquired mutations in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study. Blood. 2023;142:1890.","journal-title":"Blood"},{"key":"443_CR59","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Jones D, Jurczak W, et al. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024;144:1061\u20138.","journal-title":"Blood"},{"key":"443_CR60","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2023-174289","volume":"142","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Lamanna N, et al. Extended follow-up of ALPINE randomized phase\u00a03 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL). Blood. 2023;142:202.","journal-title":"Blood"},{"key":"443_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2017.175","volume":"32","author":"JR Brown","year":"2018","unstructured":"Brown JR, Hillmen P, O\u2019Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase\u00a03 RESONATE study in patients with previously treated CLL\/SLL. Leukemia. 2018;32:83\u201391.","journal-title":"Leukemia"},{"key":"443_CR62","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2023-179222","volume":"142","author":"M Shadman","year":"2023","unstructured":"Shadman M, Tedeschi A, Mohseninejad L, et al. Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed\/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Blood. 2023;142:4655.","journal-title":"Blood"},{"key":"443_CR63","doi-asserted-by":"publisher","first-page":"175883592513405","DOI":"10.1177\/17588359251340554","volume":"17","author":"M Shadman","year":"2025","unstructured":"Shadman M, Brown JR, Williams R, et al. Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R\/R CLL): a matching-adjusted indirect comparison (MAIC). Ther Adv Med Oncol. 2025;17:17588359251340554.","journal-title":"Ther Adv Med Oncol"},{"key":"443_CR64","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","volume":"8","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Allan JN, James D, et al. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024;8:2861\u20139.","journal-title":"Blood Adv"},{"key":"443_CR65","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.1182\/blood-2024-206560","volume":"144","author":"S Yang","year":"2024","unstructured":"Yang S, Zhu H, Feng R, et al. Efficacy and safety of zanubrutinib monotherapy in real-world Chinese CLL\/SLL patients. Blood. 2024;144:6773.","journal-title":"Blood"},{"key":"443_CR66","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1200\/JCO.2024.42.16_suppl.11158","volume":"42","author":"M Krackeler","year":"2024","unstructured":"Krackeler M, Chee B, Orchanian AK, et al. Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL\/SLL). J Clin Oncol. 2024;42:11158.","journal-title":"J Clin Oncol"},{"key":"443_CR67","first-page":"141","volume":"9","author":"CY Cheah","year":"2025","unstructured":"Cheah CY, Tam CS, Anderson M, et al. Updated results from the phase\u00a01 study of sonrotoclax (BGB-11417), a novel bcl2 inhibitor, incombination with zanubrutinib for relapsed\/refractory CLL\/SLL demonstrate deep and durable responses. Hemasphere. 2025;9:141\u20132.","journal-title":"Hemasphere"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00443-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00443-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:04:01Z","timestamp":1782385441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00443-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00443-w","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paolo Ghia has received honoraria, consulting fees and research funding from AbbVie, AstraZeneca, BeOne Medicines, Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck Sharp & Dohme, and Roche. Jennifer R Brown has received research funding from BeOne Medicines, Gilead, iOnctura, Loxo\/Lilly, MEI Pharma, Nagoon Therapeutics, and TG Therapeutics. JRB has received consulting fees from AbbVie, Acerta\/AstraZeneca, Alloplex Biotherapeutics, BeOne Medicines, Bristol-Myers Squibb, EcoR1, Galapagos NV, Genentech\/Roche, Grifols Worldwide Operations, InnoCare Pharma, Kite Pharma, Loxo\/Lilly, Magnet Biomedicine, Merck, Numab Therapeutics, Nurix Therapeutics, Pfizer, and Pharmacyclics. Mazyar Shadman has received research funding from AbbVie, AstraZeneca, BeOne, Genentech, Genmab, Morphosys\/Incyte, Mustang Bio, and Vincerx. MS has received consulting fees from AbbVie, Genentech, AstraZeneca, Genmab, Janssen, BeOne Medicines, Bristol-Myers Squibb, Morphosys\/Incyte, Kite Pharma, Eli Lilly, Fate Therapeutics, Nurix, Merck, Pfizer, and Pierre Fabre. Clemens-Martin Wendtner has received honoraria, consulting fees and research funding from AstraZeneca, BeOne Medicines, and Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors; therefore, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}